Get the Stockscreener App
7.64
6.03%
-0.49
Ocular Therapeutix Inc Stock (OCUL) Latest News
Is Ocular Therapeutix Inc (OCUL) a good investment opportunity? - US Post News
Raymond James maintains $19 target on Ocular Therapeutix stock - MSN
Ocular Therapeutix Inc (OCUL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock - Investing.com India
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock By Investing.com - Investing.com UK
There is no way Ocular Therapeutix Inc (OCUL) can keep these numbers up - SETE News
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) institutional investors lost 4.3% last week but have benefitted from longer-term gains - Simply Wall St
Ocular Therapeutix™ Announces Upcoming Presentations at the - GlobeNewswire
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - The Manila Times
Ocular Therapeutix, Inc. Announces Presentations at Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - Nasdaq
Revolutionary Eye Treatment Data: Ocular's OTX-TKI Takes Center Stage at Premier Medical Conference - StockTitan
Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Below 200 Day Moving AverageHere's What Happened - MarketBeat
SG Americas Securities LLC Buys 26,511 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India
Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
OCULOcular Therapeutix, Inc. Latest Stock News & Market Updates - StockTitan
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - The Manila Times
Ocular Therapeutix™ to Provide Corporate Update During 43rd - GlobeNewswire
Ocular Therapeutix CEO to Present AXPAXLI Trial Updates at J.P. Morgan Healthcare Conference - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Principal Financial Group Inc. - Defense World
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
Ocular Stock Is Now Thoroughly Derisked (NASDAQ:OCUL) - Seeking Alpha
Long Term Trading Analysis for (OCUL) - Stock Traders Daily
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Geode Capital Management LLC - MarketBeat
Geode Capital Management LLC Has $28.46 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 2.5%Time to Sell? - MarketBeat
State Street Corp Has $30.24 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Barclays PLC Has $4.45 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
State Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):